Skip to main content

Table 7 Main AEs’ rates (for grades 1–5) in present series compared to literature data on BZB and TH in oncology (or other) settings

From: Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia

  Present study % Literature [64,65,66,67,68,69,70,71,72] %
Bevacizumab
 Hypertension 7.2 5–19
 Bleeding 2.8 1.7–6.7
 Proteinuria 2.8 0.7–7.4
 Arterial thromboembolism 1.4 0.7–4.4
 Peripheral neuropathy Not described 6.3
Thalidomide
 Somnolence/drowsiness 16 2–23
 Peripheral neuropathy 17.9 1–44
 Thromboembolic event 2.9 1–6
 Cardiac failure 1.4 1–8
 Bleeding 1.4 Not described